Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
631 articles
RSL3-induced ferroptosis degrades SHP2 via chaperone-mediated autophagy, amplifying IFN-γ/STAT1 signaling and enhancing anti-PD-1 immunotherapy efficacy.
Cancer cells exploit cholesterol biosynthesis to keep PD-L1 high, silencing T cells — and blocking this pathway restores anti-tumor immunity.
Scientists uncover how SCRN1 blocks ferroptosis in liver cancer, revealing new targets for treating drug-resistant hepatocellular carcinoma.
Synthetic super-enhancers hijack glioblastoma's own regulatory circuits to trigger precise, tumor-only cell death and durable immune memory.
New review reveals how HER2 reshapes the tumor immune environment — and why beating it requires more than blocking the oncogene.
Researchers uncover how cancer cells evade ADC therapy by suppressing drug uptake — and identify a drug target to reverse resistance.
Inqovi gains approval for newly diagnosed AML in patients 75+ or with comorbidities, offering a gentler oral treatment route.
Mechanical tension in the tumor microenvironment controls iron metabolism and cell death susceptibility via a novel NCOA4-FTH1 autophagy axis.
Scientists identify how the HMBOX1-HACE1-ATG5 axis suppresses autophagy to restore 5-FU chemosensitivity in colorectal cancer.
A randomized trial shows hydroxychloroquine and everolimus can dramatically reduce dormant tumor cells in breast cancer survivors, potentially preventing relapse.
A pyruvate metabolism enzyme suppresses leucine catabolism to keep mTOR active in liver cancer — and blocking it shrinks tumors in vivo.
A first-in-human Phase 1 trial evaluates PF-07257876, a dual-checkpoint bispecific antibody targeting both CD47 and PD-L1, in hard-to-treat cancers.
